Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026

Same author

KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of <i>MUC1</i> Genotype.

Journal of clinical medicine·2026

Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026

Same author

Toll interacting protein (TOLLIP) serum concentration in patients with systemic sclerosis (SSc), with and without interstitial lung disease (ILD).

BMJ open respiratory research·2026

Same author

Characterization of CT Imaging-Derived Pulmonary Vascular Abnormalities Associated With Pulmonary Hypertension in Chronic Lung Disease.

Chest·2026

Same author

Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.

Medicina (Kaunas, Lithuania)·2026

Same journal

Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.

Archivos de bronconeumologia·2026

Same journal

Thoracic Sympathectomy for Harlequin Syndrome.

Archivos de bronconeumologia·2026

Same journal

Prognostic Significance of Electrocardiographic Findings in Hemodynamically Stable Patients With Acute Pulmonary Embolism: Insights From the RIETE Registry.

Archivos de bronconeumologia·2026

Same journal

Endothelial and Angiogenic Biomarkers in Obstructive Sleep Apnea: Longitudinal Associations With Continuous Positive Airway Pressure.

Archivos de bronconeumologia·2026

Same journal

Robotic Resection of Ectopic Paratracheal Thymoma: A Case Report.

Archivos de bronconeumologia·2026

Same journal

Real-World Effectiveness of Tezepelumab Across T2 and Non-T2 Severe Asthma Phenotypes: A Multicenter Spanish Cohort Study.

Archivos de bronconeumologia·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Advances in Sarcoidosis.

Juan Jose Zapata-Huizi¹, Joel Francesqui², Natalia Rivera³

¹Interstitial Lung Diseases Unit, Member of the European Reference Network-Lung, Pneumology Department, Respiratory Clinical Institute, Hospital Clínic, Barcelona, Spain.

Archivos De Bronconeumologia

|July 2, 2026

Summary

This summary is machine-generated.

Recent advances in sarcoidosis management offer improved diagnostics and personalized treatments. New imaging techniques and targeted therapies promise earlier detection and less toxic, more effective care for this complex granulomatous disease.

Keywords:

Biomarkers Corticosteroids Cryobiopsy Granulomatous disease Sarcoidosis Targeted therapy

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Area of Science:

Immunology
Pulmonology
Cardiology
Radiology
Pharmacology

Background:

Sarcoidosis is a complex systemic granulomatous disease with diverse presentations, posing diagnostic and therapeutic challenges.
Genetic and environmental factors contribute to sarcoidosis's wide phenotypic variation.
Recent years have seen significant advancements in understanding and managing sarcoidosis.

Purpose of the Study:

To review recent breakthroughs in the diagnosis and treatment of sarcoidosis.
To highlight emerging diagnostic tools and therapeutic strategies.
To discuss the shift towards personalized and less toxic sarcoidosis management.

Main Methods:

Review of recent randomized controlled trials and clinical evidence.
Analysis of novel diagnostic imaging techniques including EBUS-guided cryobiopsy, FDG-PET/CT, and cardiac MRI.
Evaluation of emerging therapeutic agents such as JAK inhibitors, PDE-4 inhibitors, and SGLT-2 inhibitors.

Main Results:

EBUS-guided cryobiopsy shows improved diagnostic yield.
Advanced imaging biomarkers enhance precision and prognostic value in sarcoidosis.
New treatment paradigms shift away from corticosteroid-centric models, with methotrexate showing promise as a first-line option.
Targeted therapies demonstrate preliminary efficacy in specific sarcoidosis manifestations.

Conclusions:

Advances in diagnostics and therapeutics are transforming sarcoidosis management.
The future of sarcoidosis care involves earlier, less invasive detection and personalized, targeted therapies.
These developments pave the way for more precise, less toxic, and individualized treatment approaches for sarcoidosis patients.